Accord Healthcare C/O Qestmed Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Accord Healthcare C/O Qestmed Pharmaceutical Import Records from India — 3 Products, $580.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare C/O Qestmed — Pharmaceutical Importer Profile (2026) | 3 Products, $580.6K Trade | TransData Nexus

Accord Healthcare C/O Qestmed

Pharmaceutical Importer · South Africa · Oncology Focus · $580.6K Total Trade · DGFT Verified

Accord Healthcare C/O Qestmed is a pharmaceutical importer based in South Africa with a total trade value of $580.6K across 3 products in 2 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare C/O Qestmed sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare C/O Qestmed — Import Portfolio & Supplier Network

Accord Healthcare C/O Qestmed import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare C/O Qestmed?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$4.4M	187	100.0%

Accord Healthcare C/O Qestmed sources from 1 verified Indian supplier across 117 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Phr drugs&medi bonrix ibandronic acid6mg	$150.0K	3
Pharma drugs and medi irinotas 100 (20 MG/ML 5ML Each ML contains irinotecan hcl trihydrate	$150.0K	3
Pharma drugs & medi accord-carboplatin	$148.8K	4
Pharma drugs and medi accord epirubicin50mg (2MG/ML 25ML) 1v as per	$144.2K	6
Pharmaceutical drugs & medicine capexa capecitabine 500MG 12x10t(acc-sa Each film coated tablet conts:capecitabine	$120.5K	6
Pharma drugs & medi capexa capecitabine500 MG 12x10t(acc-sa as per	$119.3K	3
Pharma drugs and medi tarograf tacrolimus 1 MG 30c as per	$116.6K	3
Pharma drugs & medi capexa	$107.8K	4
Pharma drugs and medi rubexet 50MG (2MG/ML 25ML) as per	$102.8K	6
Pharma drugs & medi accord letrozole	$100.0K	2
Pharma drugs and medi irinotas 100 (20 MG/ML, 5ML Each ML contains irinotecan hcl trihydrate 20MG.	$100.0K	2
Pharma drugs & medi accord	$94.3K	2
Pharmaceutical drugs and medicine -	$78.2K	3
Pharma drugs and medi epicord 50 epirubicin hcl 2MG/ml25ml1v as per	$77.2K	3
Pharma drugs and medi stradexa 1 MG 3 x10 TAB as per	$72.6K	3

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Irinotecan	Oncology	$300.0K	6	0.7%	12
2	Epirubicin	Advanced Oncology	$251.2K	12	3.9%	5
3	Vincristine	Oncology	$29.4K	2	1.5%	6

Accord Healthcare C/O Qestmed imports 3 pharmaceutical products across 2 categories into South Africa totaling $580.6K.

Accord Healthcare C/O Qestmed — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare C/O Qestmed is a pharmaceutical importer and buyer based in South Africa, specializing in the acquisition of finished pharmaceutical formulations from India. The company operates under the auspices of Accord Healthcare, a global pharmaceutical entity renowned for developing, manufacturing, and distributing generic, biosimilar, and added-value medicines across over 85 countries. Accord Healthcare's South African operations are headquartered at 20 Woodlands Drive, Woodmead, Gauteng 2191, South Africa. (accordhealth.co.za)

In the South African pharmaceutical distribution landscape, Accord Healthcare C/O Qestmed plays a pivotal role by sourcing essential medicines from India to meet local demand. Their focus on finished pharmaceutical formulations ensures that patients have access to ready-to-use medications, thereby enhancing the efficiency of the healthcare supply chain. This strategic sourcing aligns with Accord Healthcare's mission to improve access to vital pharmaceutical care at the point of need.

2Distribution Network

Accord Healthcare C/O Qestmed's distribution network in South Africa is centered around its headquarters in Woodmead, Gauteng. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Gauteng—a province known for its robust infrastructure and proximity to major transport hubs—facilitates efficient distribution across the country. This central location enables timely delivery of pharmaceutical products to various regions within South Africa, ensuring that healthcare providers and patients have reliable access to essential medications.

3Industry Role

In South Africa's pharmaceutical supply chain, Accord Healthcare C/O Qestmed functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from India, the company acts as an intermediary between Indian manufacturers and the South African market. This role is crucial in ensuring the availability of a diverse range of medications, particularly in therapeutic areas such as oncology, cardiology, and urology, thereby supporting the healthcare system's capacity to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare C/O Qestmed

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare C/O Qestmed's sourcing strategy exhibits a high degree of concentration, with a total import value of $581,000 USD from India across 20 shipments, all supplied by a single Indian manufacturer, Intas Pharmaceuticals Limited. This exclusive sourcing arrangement indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply. However, this single-source dependency also introduces risks, including vulnerability to supply chain disruptions, regulatory changes in India, or shifts in the supplier's operational capacity. The absence of alternative suppliers may limit the company's flexibility in responding to market fluctuations or diversifying its product offerings.

2Supply Chain Resilience

The resilience of Accord Healthcare C/O Qestmed's supply chain is closely tied to its exclusive relationship with Intas Pharmaceuticals Limited. While this partnership may ensure consistent product quality and supply, the lack of backup suppliers could pose challenges in the event of disruptions. The company's focus on finished pharmaceutical formulations imported from India suggests a reliance on specific shipping routes and regulatory compliance standards. To enhance supply chain resilience, it would be prudent for Accord Healthcare C/O Qestmed to consider diversifying its supplier base and exploring alternative sourcing options.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

The South African Health Products Regulatory Authority (SAHPRA) is the primary body responsible for regulating the importation, distribution, and sale of medicines in South Africa. Operating under the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), SAHPRA ensures that all health products meet the required quality, safety, and efficacy standards. For Indian generics to be marketed in South Africa, they must undergo a registration process with SAHPRA, which evaluates the product's compliance with these standards. (sahpra.org.za)

2Import Licensing & GMP

To import medicines into South Africa, companies must obtain a license from SAHPRA, which authorizes them to import and distribute pharmaceutical products. Additionally, the South African Pharmacy Council requires that pharmaceutical manufacturers and wholesalers be licensed and recorded as a manufacturing or wholesale pharmacy. Compliance with Good Manufacturing Practices (GMP) is mandatory, and SAHPRA issues guidelines related to GMP to ensure that imported medicines meet international quality standards.

3Quality & Labeling

Accord Healthcare C/O Qestmed — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare C/O Qestmed's focus on importing oncology and advanced oncology medications aligns with the growing demand for cancer treatments in South Africa. The substantial import values of Irinotecan ($300K) and Epirubicin ($251K) indicate a strategic emphasis on these critical therapeutic areas. This focus is driven by the increasing prevalence of cancer and the need for accessible, high-quality treatment options. By concentrating on these categories, Accord Healthcare C/O Qestmed aims to address significant gaps in the South African healthcare system and improve patient outcomes.

2Sourcing Profile

Accord Healthcare C/O Qestmed's sourcing strategy is centered on generic drugs, particularly in the oncology sector. The company's exclusive partnership with Intas Pharmaceuticals Limited for finished pharmaceutical formulations from India reflects a preference for established suppliers with a proven track record in quality and reliability. This approach ensures that imported products meet the stringent standards required by South African regulations, thereby facilitating smoother market entry and acceptance.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Healthcare C/O Qestmed

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the South African market by offering competitive oncology products that meet SAHPRA's regulatory standards. Accord Healthcare C/O Qestmed's current sourcing strategy, which relies on a single supplier, presents an opportunity for diversification. Indian exporters can leverage this by providing alternative products that align with Accord Healthcare C/O Qestmed's therapeutic focus, thereby enhancing the company's product portfolio and reducing supply chain risks.

2Requirements & Qualifications

Indian exporters aiming to supply Accord Healthcare C/O Qestmed must ensure that their products are registered with SAHPRA and comply with South African GMP standards. Additionally, they must adhere to labeling requirements, including English language specifications and compliance with the Medicines and Related Substances Act, 1965. Obtaining the necessary import licenses and ensuring that products meet batch testing and stability requirements are also essential steps in the qualification process.

3How to Approach

Frequently Asked Questions — Accord Healthcare C/O Qestmed

What products does Accord Healthcare C/O Qestmed import from India?

Accord Healthcare C/O Qestmed imports 3 pharmaceutical products across 2 categories. Top imports: Irinotecan ($300.0K), Epirubicin ($251.2K), Vincristine ($29.4K).

Who supplies pharmaceuticals to Accord Healthcare C/O Qestmed from India?

Accord Healthcare C/O Qestmed sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $4.4M).

What is Accord Healthcare C/O Qestmed's total pharmaceutical import value?

Accord Healthcare C/O Qestmed's total pharmaceutical import value from India is $580.6K, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare C/O Qestmed focus on?

Accord Healthcare C/O Qestmed imports across 2 categories. The largest: Oncology (56.7%), Advanced Oncology (43.3%).

Get Full Accord Healthcare C/O Qestmed Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.